186 related articles for article (PubMed ID: 36855295)
1. The significance of upfront autologous stem cell transplantation for high-intermediate/high-risk stage IV diffuse large B-cell lymphoma.
Koviazin AK; Filatova LV; Zyuzgin IS; Artemyeva AS; Poliatskin IL; Burda DS; Volchenkov SA; Elkhova SS; Semiglazova TY
Cancer Rep (Hoboken); 2023 Apr; 6(4):e1786. PubMed ID: 36855295
[TBL] [Abstract][Full Text] [Related]
2. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
3. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
4. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation for Patients with Diffuse Large B-Cell Lymphoma].
Fan D; Liu Q; Xiao F; Guo HX; Zhao H; Yan XQ; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1163-1168. PubMed ID: 34362497
[TBL] [Abstract][Full Text] [Related]
6. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
[TBL] [Abstract][Full Text] [Related]
7. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
Kagami Y; Yamamoto K; Shibata T; Tobinai K; Imaizumi Y; Uchida T; Shimada K; Minauchi K; Fukuhara N; Kobayashi H; Yamauchi N; Tsujimura H; Hangaishi A; Tominaga R; Suehiro Y; Yoshida S; Inoue Y; Suzuki S; Tokuhira M; Kusumoto S; Kuroda J; Yakushijin Y; Takamatsu Y; Kubota Y; Nosaka K; Morishima S; Nakamura S; Ogura M; Maruyama D; Hotta T; Morishima Y; Tsukasaki K; Nagai H
Cancer Sci; 2020 Oct; 111(10):3770-3779. PubMed ID: 32767806
[TBL] [Abstract][Full Text] [Related]
8. High-dose Chemotherapy Combined with Autologous Hematopoietic Stem Cell Transplantation as Frontline Therapy for Intermediate/High-risk Diffuse Large B Cell Lymphoma.
Wen Q; Gao L; Xiong JK; Li Q; Wang SB; Wang JS; Liu F; Zhang C; Liu Y; Kong PY; Peng XG; Rao J; Gao L; Zhang X
Curr Med Sci; 2021 Jun; 41(3):465-473. PubMed ID: 34218355
[TBL] [Abstract][Full Text] [Related]
9. [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].
Zhao SX; Han Y; Zhu Q; Wang Q; Zhang WJ; Chen XC; Sun AN; Jin ZM; Qiu HY; Tang XW; Fu ZZ; He GS; Miao M; Ma X; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):623-7. PubMed ID: 23815910
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).
Murayama T; Fukuda T; Okumura H; Sunami K; Sawazaki A; Maeda Y; Tsurumi H; Uike N; Hidaka T; Takatsuka Y; Eto T; Tsuda H; Fujisaki T; Miyamoto T; Tsuneyoshi N; Iyama S; Nagafuji K; Harada M
Int J Hematol; 2016 Jun; 103(6):676-85. PubMed ID: 27084252
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation].
Ying ZT; Mi L; Wang XJ; Zhang YW; Yang Z; Song YQ; Wang XP; Zheng W; Lin NJ; Tu MF; Xie Y; Ping LY; Zhang C; Liu WP; Deng LJ; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):382-386. PubMed ID: 29779346
[No Abstract] [Full Text] [Related]
12. Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial.
Kobayashi T; Yamamoto K; Kagami Y; Machida R; Miyazaki K; Nakamura S; Kuroda J; Maruyama D; Nagai H
Jpn J Clin Oncol; 2022 May; 52(6):583-588. PubMed ID: 35353186
[TBL] [Abstract][Full Text] [Related]
13. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
14. [Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma].
Yi S; Liu W; Lyu R; Li Z; Xu Y; Sui W; Huang W; Wang T; Deng S; Liu H; Fu M; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):546-50. PubMed ID: 24985182
[TBL] [Abstract][Full Text] [Related]
15. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
16. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
[TBL] [Abstract][Full Text] [Related]
17. [Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma].
Wang P; Li CX; Zhang Y; Chen J; Chen XC; Yang D; Zhou J; Zong XP; Yang Z; Wu M; Yang MZ; Song YQ; Zhu J; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):198-203. PubMed ID: 32311888
[No Abstract] [Full Text] [Related]
18. R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma.
Lee HG; Choi Y; Kim SY; Kim I; Kim YK; Kim YS; Lee HS; Kim SJ; Kim JA; Park BB; Park J; Shim H; Eom HS; Lee J; Park SK; Cheong JW; Park KW
Blood Res; 2014 Jun; 49(2):107-14. PubMed ID: 25025012
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.
Malenda A; Kołkowska-Leśniak A; Puła B; Długosz-Danecka M; Chełstowska M; Końska A; Giza A; Lech-Marańda E; Jurczak W; Warzocha K
Eur J Haematol; 2020 Jan; 104(1):59-66. PubMed ID: 31606909
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of
Ying Z; Mi L; Zhou N; Wang X; Yang Z; Song Y; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Zhu J
Chin J Cancer Res; 2019 Feb; 31(1):162-170. PubMed ID: 30996574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
